A Multi-society Effort Is Driving Imaging Interoperability Across Healthcare
A collaboration among DPA, CAP and SIIM is helping standardize imaging workflows, enabling AI, analytics and enterprise data sharing
A collaboration among DPA, CAP and SIIM is helping standardize imaging workflows, enabling AI, analytics and enterprise data sharing
The combination of AI and advanced signal processing, along with innovations in digital and wearable tech, places us in a moment where providers will soon be able to have high-quality data that presents the opportunity to shift from reactive heart failure treatment to preventive cardiac care. The post The Moment is Now: Preventive Cardiac Care…
On Fridays, Stephanie Johnson has a busy schedule, driving her navy-blue Jeep from one patient’s home to the next, seeing eight in all. Pregnant with her second child, she schleps a backpack instead of a traditional black bag to carry a laptop and essential medical supplies — stethoscope, blood pressure cuff, and pulse oximeter. Forget…
“We’re done with junk science,” RFK Jr. said in a news conference on Thursday
Digital health funding remains strong so far this year, with $9.9 billion raised through Q3 and megarounds driving record deal sizes. However, the path to scale is becoming less predictable, as startups increasingly rely on unlabeled rounds and face longer timelines to reach Series B. The post Inside a Big Q3: Venture Capital for Digital…
Innovaccer is committing $250 million to expand its AI agent platform, which automates workflows across areas like prior authorization, revenue cycle management and population health. The move comes amid an ongoing debate over whether administrative AI tools can ultimately reduce costs for providers. The post Why Innovaccer Is Pouring $250M into Its Agentic AI Platform…
By STEVEN ZECOLA The United States healthcare system has failed by any measure. First, costs are out of control. For example, 17% of the country’s GDP is spent on healthcare. This percentage was less than half that amount in 1980. It is expected to continue growing to 20% by 2032. Seventy-five percent of these costs are attributable to…
This edition highlights vaccine hesitancy and misinformation around MMR (measles, mumps, and rubella) vaccines as children return to school and measles cases resurge in parts of the U.S. It also examines emerging narratives around COVID-19 vaccine misinformation following the FDA approval of COVID-19 boosters and false claims linking mpox to the vaccines.
There are no FDA-approved therapies for GPC3, a protein highly expressed by liver cancers. Oricell Therapeutics claims its cell therapy could be best in this class, but it faces competition from companies such as AstraZeneca and Eureka Therapeutics. The post Oricell Lands $110M to Take Cell Therapy to New Territory in Cancer appeared first on…